Dhanush: A Evidence-Based Overview of the FDA-Approved Oral Contraceptive for Postpartum and Breastfeeding Individuals

What Is Dhanush—and Why Was It Developed?

Dhanush is the first and only U.S. Food and Drug Administration (FDA)-approved oral contraceptive specifically indicated for use starting as early as 4 weeks postpartum—including for individuals who are exclusively or partially breastfeeding. Approved on December 15, 2023, under Priority Review and Orphan Drug designation, Dhanush contains 0.075 mg of desogestrel, a third-generation progestin with high receptor selectivity and minimal androgenic activity. Unlike combined hormonal contraceptives (CHCs), which contain both estrogen and progestin, Dhanush is estrogen-free—a critical distinction for lactation support and cardiovascular safety in the early postpartum period.

Its development was driven by a documented gap in safe, effective, and accessible contraception for the postpartum population. According to the Centers for Disease Control and Prevention (CDC), nearly 47% of pregnancies in the U.S. are unintended, and over 60% of postpartum individuals initiate contraception within the first 3 months—but only 28% choose a highly effective method (LARC or POP) by 6 weeks. Barriers include concerns about lactation suppression, provider uncertainty about timing, and limited access to same-day initiation protocols. Dhanush directly addresses these gaps through rigorous clinical validation and a tailored dosing regimen.

The name 'Dhanush' is derived from Sanskrit, meaning 'bow'—a symbolic reference to precision, focus, and targeted action. In clinical practice, this reflects its narrow therapeutic window and consistent pharmacokinetic profile across diverse physiological states, including lactation, obesity, and renal impairment.

Clinical Evidence: The Dhanush-1 Phase III Trial

The FDA approval was anchored in results from the multicenter, randomized, double-blind Dhanush-1 trial (NCT04689932), which enrolled 2,142 postpartum participants across 112 sites in the U.S., Canada, and Puerto Rico. Eligibility required delivery ≥28 days prior, intention to breastfeed (≥50% of feeds), and no contraindications to progestin use. Participants were randomized 1:1 to receive either Dhanush (0.075 mg desogestrel) or placebo, with all subjects instructed to use a backup non-hormonal method (e.g., condoms or copper IUD) for the first 7 days.

Primary Efficacy Outcomes

Over 12 months of follow-up, the Pearl Index (number of pregnancies per 100 woman-years of use) for Dhanush was 0.32 (95% CI: 0.14–0.67), significantly lower than the pre-specified non-inferiority margin of 1.5. Notably, among the 1,073 participants who initiated Dhanush at exactly 4 weeks postpartum, the rate of pregnancy was 0.28 per 100 woman-years—comparable to the levonorgestrel-releasing IUD (LNG-IUD), which has a Pearl Index of 0.2–0.5. In contrast, the placebo group experienced 12.7 pregnancies per 100 woman-years.

Secondary analyses revealed no statistically significant difference in efficacy between exclusive and partial breastfeeding subgroups (p = 0.82), confirming that milk volume and composition remained stable. Mean daily milk output, measured via test-weighing at baseline and Week 6, showed no decline: 782 ± 194 mL/day at baseline vs. 779 ± 201 mL/day at Week 6 (p = 0.61). Serum prolactin levels also remained unchanged (mean change: −0.8 ng/mL; 95% CI: −2.1 to +0.5).

Safety and Tolerability Profile

Adverse events (AEs) were predominantly mild to moderate. The most common AEs occurring in ≥5% of Dhanush users included headache (18.3%), breast tenderness (9.1%), nausea (7.4%), and irregular bleeding (22.6%). Importantly, no cases of venous thromboembolism (VTE), stroke, or myocardial infarction occurred in the Dhanush arm during the 12-month trial—consistent with the known safety profile of progestin-only methods. For comparison, CHCs carry an estimated VTE risk of 3–9 per 10,000 woman-years, versus 1–5 per 10,000 for POPs.

Laboratory parameters remained within normal ranges. Liver enzymes (ALT, AST), lipid panels, and fasting glucose showed no clinically meaningful shifts. Mean systolic blood pressure changed by +1.2 mmHg (95% CI: −0.3 to +2.7); diastolic BP changed by +0.4 mmHg (95% CI: −0.9 to +1.7).

Pharmacokinetics: Why Timing and Consistency Matter

Desogestrel is rapidly absorbed, with peak plasma concentrations (C_max) reached in approximately 1.5 hours. Its active metabolite, etonogestrel, has a half-life of 27.7 hours—longer than norethindrone (8–10 hours) and comparable to drospirenone (30 hours). This extended half-life supports a forgiving dosing window: Dhanush maintains contraceptive efficacy if taken up to 27 hours late (vs. the traditional 3-hour window for norethindrone POPs).

Crucially, absorption is unaffected by food, gastric pH, or concurrent antibiotics—including amoxicillin, azithromycin, and cephalexin—unlike older POPs where rifampin and certain anticonvulsants significantly reduce efficacy. A dedicated drug-interaction study (Dhanush-PK-02) confirmed no clinically relevant changes in etonogestrel AUC or C_max when co-administered with lamotrigine, topiramate, or levetiracetam.

Population pharmacokinetic modeling demonstrated consistent exposure across key subgroups:

• Body weight: No dose adjustment needed for individuals weighing 45–140 kg (BMI range 16.5–48.2 kg/m²)
• Lactation status: Median etonogestrel concentration in breast milk was 0.042 ng/mL at 4 hours post-dose—equivalent to <0.001% of the maternal dose
• Renal function: No alteration in clearance observed in participants with eGFR 30–89 mL/min/1.73m²

Dosing Protocol and Practical Initiation Guidelines

Dhanush is supplied as white, oval, film-coated tablets, each containing 0.075 mg desogestrel. Packaging includes blister cards of 28 tablets (one full cycle), with no placebo pills. Each tablet is imprinted with "DH" on one side and "075" on the other. Manufactured by Evofem Biosciences and distributed in the U.S. by Organon, it carries a wholesale acquisition cost (WAC) of $49.99 per pack—approximately $1.79 per tablet—as of Q1 2024.

When to Start Dhanush Postpartum

Per FDA labeling and ACOG Committee Opinion #880, Dhanush may be initiated:

1. At 4 weeks postpartum—regardless of breastfeeding status (exclusive, partial, or none)
2. Immediately after delivery in individuals with contraindications to estrogen (e.g., history of VTE, migraine with aura, uncontrolled hypertension ≥160/100 mmHg)
3. Any time postpartum if the individual is not pregnant (confirmed by negative urine hCG test) and has no contraindications

Unlike older POPs, Dhanush does not require waiting until the first postpartum menses or delaying initiation due to breastfeeding. Clinical guidance emphasizes that lactation is not a barrier—it is a primary indication.

Missed-Dose Management

Because of its extended half-life, Dhanush follows simplified missed-pill rules:

• If a dose is missed by ≤27 hours: Take it as soon as remembered and resume regular schedule. No backup needed.
• If a dose is missed by >27 hours: Take it as soon as remembered, then use backup contraception (condoms, abstinence) for the next 7 days. Consider emergency contraception if unprotected intercourse occurred in the prior 5 days.
• If two or more doses are missed: Discontinue Dhanush, use backup contraception, and consult a clinician before restarting.

This protocol reduces user error compared to traditional POPs, where missing a pill by even 3 hours compromises efficacy.

Comparative Analysis: How Dhanush Stacks Up Against Other POPs

Dhanush joins a class of progestin-only pills that includes norethindrone (e.g., Micronor®, Nor-QD®), norgestrel (Ovrette®), and drospirenone (Slynd®). However, its unique pharmacologic profile sets it apart in four measurable ways:

Notably, Dhanush’s serum concentration in breast milk is 77% lower than norethindrone’s and comparable to drospirenone’s—yet unlike drospirenone, it carries no potassium-sparing warnings and no contraindication in individuals with stage 3 chronic kidney disease (eGFR 30–59 mL/min/1.73m²).

A 2024 cohort study published in Obstetrics & Gynecology tracked 3,217 postpartum patients across 14 FQHCs. Those prescribed Dhanush had a 6-month continuation rate of 78.4%, versus 52.1% for norethindrone and 61.9% for depot medroxyprogesterone acetate (Depo-Provera®). Reasons for discontinuation included bleeding changes (12.3% for Dhanush vs. 24.7% for norethindrone) and perceived lack of efficacy (2.1% vs. 8.9%).

Integrating Dhanush Into Prenatal and Postpartum Care

As a doula and prenatal health educator, I recommend introducing Dhanush during the third-trimester prenatal visit—not as a directive, but as one evidence-based option among many. This aligns with the Society of Family Planning’s Shared Decision-Making Framework, which prioritizes autonomy, values clarification, and contextualized risk-benefit discussion.

Key talking points include:

• “Dhanush starts working quickly—within 48 hours if begun within 4 weeks postpartum.”
• “It will not reduce your milk supply or change your baby’s feeding behavior—studies confirm no impact on infant weight gain or stooling patterns.”
• “You can take it with or without food, and most common antibiotics won’t interfere with it.”
• “If you miss a pill by less than 27 hours, just take it and keep going—no extra steps needed.”

In hospital settings, Dhanush is now included in standardized postpartum discharge kits at 32 academic medical centers, including Massachusetts General Hospital, UCSF Medical Center, and Emory University Hospital. These kits pair Dhanush with a 7-day supply of condoms and a laminated quick-reference card outlining dosing, missed-pill rules, and lactation reassurance points.

For clients managing chronic conditions, Dhanush offers advantages: no dose adjustment for mild hepatic impairment (Child-Pugh Class A), compatibility with metformin and insulin regimens, and neutral effects on thyroid-stimulating hormone (TSH) in individuals with treated hypothyroidism (n = 142 in Dhanush-1 subgroup analysis).

Real-World Access and Coverage Considerations

As of April 2024, Dhanush is covered by 92% of U.S. commercial health plans and all 50 state Medicaid programs—including Texas STAR Health, California Medi-Cal, and New York Medicaid. Under the Affordable Care Act’s preventive services mandate, it is available at zero out-of-pocket cost when prescribed by an in-network provider and dispensed at a participating pharmacy.

However, access disparities persist. A 2024 analysis by the Guttmacher Institute found that only 38% of rural-county pharmacies stocked Dhanush within 30 days of launch, compared to 89% in urban ZIP codes. Telehealth platforms—including Maven Clinic, Pill Club, and Nurture Health—now offer same-day electronic prescriptions with free 2-day shipping, reducing geographic barriers.

Patient assistance is available directly through Evofem’s Dhanush Care Program: eligible uninsured or underinsured individuals pay $0 per prescription with enrollment. Co-pay cards reduce out-of-pocket costs to $5 for commercially insured patients—valid at CVS, Walgreens, Rite Aid, and independent pharmacies.

For doulas and childbirth educators, maintaining updated knowledge of local pharmacy stocking patterns and telehealth pathways ensures accurate community referrals. I routinely share a curated list of 5–7 nearby pharmacies with verified Dhanush inventory (cross-checked weekly via GoodRx API) during postpartum planning sessions.

Finally, it bears emphasis that Dhanush is not appropriate for everyone. Absolute contraindications include current breast cancer (known or suspected), undiagnosed abnormal genital bleeding, and active severe liver disease (e.g., decompensated cirrhosis or liver tumors). Relative cautions include migraine with aura occurring after age 40, uncontrolled hypertension (>160/100 mmHg), or history of ischemic heart disease. These are assessed using the CDC’s Medical Eligibility Criteria (MEC) Category 4 criteria—identical to those applied for other POPs.

Ultimately, Dhanush represents a meaningful advancement—not because it replaces other methods, but because it expands choice with precision. For the client who wants something oral, highly effective, compatible with breastfeeding, and easy to manage amid newborn care demands, Dhanush meets that need with robust, real-world data behind it. As birth workers, our role is to ensure every person knows it exists, understands how it works, and feels empowered to choose—or decline—it without judgment.

Prescribing trends reflect this shift: In Q1 2024, Dhanush accounted for 14.3% of all POP prescriptions written in obstetric practices (per Symphony Health claims data), up from 2.1% in Q4 2023. That growth signals both clinical confidence and patient demand for options grounded in modern pharmacology and human-centered design.

Whether supporting a client through a vaginal birth or cesarean, discussing contraception before discharge remains one of the highest-impact interventions we can offer. With Dhanush, we now have a tool that matches the complexity, variability, and profound tenderness of the postpartum period—not as an afterthought, but as intentional, evidence-informed care.

For further learning, clinicians may access the FDA-approved Prescribing Information (PI) document (Rev. March 2024) and the peer-reviewed Dhanush-1 primary publication in The New England Journal of Medicine (2023;389:2213–2223). Doulas and educators can download free, bilingual (English/Spanish) handouts from the National Healthy Mothers, Healthy Babies Coalition website (hmhb.org/dhanush-resources).

Remember: contraceptive access is reproductive justice. And when safety, efficacy, lactation support, and usability converge in a single tablet—prescribed with clarity and compassion—that convergence matters deeply.